‘Regenerative’ can describe a biological aim, but it is also a marketing word. A credible recommendation must identify the exact product or procedure, intended use, evidence and uncertainty.
Ask what the treatment actually contains
A brand name is not a mechanism. Is the treatment autologous, a medical device, a medicine, a topical cosmetic or a substance being used outside its intended route? Source, sterility, manufacturing consistency and instructions for use matter.
Evidence must match the claim
A laboratory study showing cell activity does not prove a visible clinical benefit. Small uncontrolled before-and-after studies are not equivalent to randomised trials, and evidence for one formulation cannot automatically be transferred to another.
Look for meaningful outcomes
Good evidence uses defined endpoints, adequate follow-up, transparent adverse-event reporting and ideally independent replication. ‘Collagen stimulation’ is not enough unless the change is clinically useful and risks are understood.
Where we remain cautious
Products described as exosomes vary substantially, and regulatory positions continue to develop. We do not treat novelty as a reason to bypass product traceability, consent or established infection-control standards.
The bottom line
The responsible question is not ‘Is it regenerative?’ It is ‘What exactly is it, what evidence supports this use, and is the likely benefit worth the risk?’Editorial note: information checked August 2026. This article is general education, not personal medical advice. Suitability and risk must be assessed individually.